Risks and Benefits of Bisphosphonate Therapies

Carlen Reyes, Mette Hitz, Daniel Prieto-Alhambra, Bo Abrahamsen

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstrakt

Bisphosphonates are the mainstay of osteoporosis treatment but also play a fundamental role in treating other bone diseases such as Osteogenesis Imperfecta, Pagets' disease, and in the prevention of adverse skeletal effects in certain cancers such as prostate cancer or multiple myeloma. In the last decades, the refinement of bisphosphonates and an increase in the number of new bisphosphonates commercialized has altered the clinical management of these diseases. Despite differences between randomized controlled trials and observational studies, overall all bisphosphonates licensed have proven to reduce the risk of fracture through the inhibition of bone resorption. Other beneficial effects include pain reduction in bone metastasis and potentially a decrease in mortality. However, the chronic nature of most of these disorders implies long-term treatments, which can be associated with long-term adverse effects. Some of the adverse effects identified include an increased risk of atypical femur fractures, osteonecrosis of the jaw, gastrointestinal side effects, or atrial fibrillation. The harm/benefit thinking and the constant update regarding these medications are vital in the day-to-day decision-making in clinical practices. The aims of this review are to compile the basic characteristics of these drugs and outline the most important benefits and side effects and provide a clinical context as well as a research agenda to fill the gaps in our knowledge.

OriginalsprogEngelsk
Sider (fra-til)20-28
Antal sider9
TidsskriftJournal of Cellular Biochemistry
Vol/bind117
Udgave nummer1
DOI
StatusUdgivet - 1 jan. 2016

Fingeraftryk Udforsk hvilke forskningsemner 'Risks and Benefits of Bisphosphonate Therapies' indeholder.

Citationsformater